Blueprint Medicines Corp. has disclosed EGFR (L858R/T790M/C797S triple mutant) and/or EGFR (exon 19 deletion mutant) inhibitors reported to be useful for the treatment of cancer.

CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co. Ltd. has described pyrimidine and nitrogen-containing 6-membered aromatic heterocyclic compounds acting as S-adenosylmethionine synthase isoform type-2 (Mat2A) inhibitors reported to be useful for the treatment of cancer.

Jiangsu Chia Tai Tianqing Pharmaceutical Group Co. Ltd. has divulged 1,2,4-triazole compounds acting as tyrosine-protein kinase receptor UFO (AXL) inhibitors reported to be useful for the treatment of cancer.

The Consejo Superior de Investigaciones Cientificas (CSIC) has identified chemokine CXCR4 (SDF-1 receptor) receptor ligands reported to be useful for the treatment of cancer, rheumatoid arthritis and AIDS.

Chengdu Easton Biopharmaceuticals Co. Ltd. has synthesized ATR kinase inhibitors reported to be useful for the treatment of cancer.

Sichuan Huiyu Pharmaceutical Co. Ltd. and Sichuan Huiyu Seacross Pharma Technology Ltd. have disclosed derivatives with pyrimidine-fused cyclic structures acting as son of sevenless homolog 1 (SOS1) inhibitors reported to be useful for the treatment of cancer, cardiofaciocutaneous and Noonan syndromes.

Cedilla Therapeutics Inc. has synthesized cyclin-dependent kinase 2 (CDK2)/cyclin E1 inhibitors reported to be useful for the treatment of cancer, autoimmune diseases, Cushing syndrome, Alzheimer's disease, hepatic fibrosis, viral infections, inflammatory disorders and polycystic kidney.

Gilgamesh Pharmaceuticals Inc. has identified arylcyclo-hexylamine derivatives targeting N-methyl-D-aspartate receptor (NMDAR) and/or serotonin transporter (SERT) reported to be useful for the treatment of substance abuse and dependence, depression and mood and anxiety disorders.

LG Chem has described urea derivatives acting as macrophage stimulating 1 receptor (MST1R; RON) inhibitors reported to be useful for the treatment of cancer and immunological disorders.

Insilico Medicine Inc. has divulged β-lactam derivatives acting as glutaminyl-peptide cyclotransferase-like protein (QPCTL) inhibitors reported to be useful for the treatment of cancer, Alzheimer's diseases, atherosclerosis, chronic kidney disease, infertility, ischemia-reperfusion injury, schizophrenia and Zollinger-Ellison syndrome, among others.